Skip to content

Drug Sale Permit Cancelled After Sipla’s Reactin Plus Violations

By News Analysis India · · 1 min read

In a decisive move, the state drug authority has annulled the sales licence of Sipla Pharma’s carry‑and‑forward unit after identifying multiple infractions tied to its Reactin Plus tablets. The inspection team flagged unauthorised health claims on the product’s label, a direct breach of the Drugs and Cosmetics Act, 1940 and its 1945 regulations.

The agency seized over ₹1 million worth of stock and demanded its removal from the market. Sipla’s non‑compliance with the recall order led to the final revocation of its licence.

Officials highlighted that promoting prescription drugs without a doctor’s prescription can foster self‑treatment, compromising public health. Further investigations uncovered inconsistencies in both physical and computerized inventory logs, incomplete purchase‑sale records, and failure to follow recall instructions.

Storage conditions were also substandard: medicines were placed directly on the ground, lacking appropriate pallets or shelving, and expired items were not properly recorded or disposed of.

The FDA’s commissioner affirmed a strict stance, promising rigorous enforcement of drug safety regulations and swift legal action against any entity that flouts the rules.